Bitcoin is once again in the spotlight as Standard Chartered predicts a potential record-breaking rally. The bank’s Head of Digital Assets Research, Geoffrey Kendrick, reaffirmed his target of $200,000 for the world’s largest cryptocurrency by the end of the year. He noted that if the ongoing U.S. government shutdown continues, Bitcoin’s correlation with Treasury term […]Bitcoin is once again in the spotlight as Standard Chartered predicts a potential record-breaking rally. The bank’s Head of Digital Assets Research, Geoffrey Kendrick, reaffirmed his target of $200,000 for the world’s largest cryptocurrency by the end of the year. He noted that if the ongoing U.S. government shutdown continues, Bitcoin’s correlation with Treasury term […]

Standard Chartered Sees Bitcoin Hitting $135K Soon, $200K by Year-End

2025/10/06 13:00
3 min read
For feedback or concerns regarding this content, please contact us at [email protected]
Bitcoin
  • Bitcoin is trading near its August high, with forecasts pointing toward $200,000 by year-end.
  • ETF inflows have surged to $3.24 billion, marking the second-best week since launch.
  • Market sentiment is improving amid expectations of a U.S. interest rate cut and the ongoing government shutdown.

Bitcoin is once again in the spotlight as Standard Chartered predicts a potential record-breaking rally. The bank’s Head of Digital Assets Research, Geoffrey Kendrick, reaffirmed his target of $200,000 for the world’s largest cryptocurrency by the end of the year.

He noted that if the ongoing U.S. government shutdown continues, Bitcoin’s correlation with Treasury term premiums could push prices higher. Currently, BTC trades at $123,276.84, hovering just below its August peak of $124,480.

According to Kendrick, BTC could reach $135,000 in the coming weeks, slightly later than his earlier projection. He also highlighted that strong exchange-traded fund inflows and favorable macroeconomic trends could drive the next leg of the rally.

Also Read: Strategy Now Holds $77.4 Billion in Bitcoin, Surpassing Global Banks in Value

Bitcoin ETF Inflows Signal Renewed Investor Confidence

U.S.-listed spot Bitcoin exchange funds have gone into October with a bang. They had cumulative net inflows of $3.24 billion in the last week, close to their all-time high of $3.38 billion in November 2024.

Data from SoSoValue shows that the numbers mark a brisk rebound from the previous week’s withdrawals of $902 million.

Digit asset exchange Nexo’s dispatch expert Iliya Kalchev stated that the recovery was due to growing hopes for another U.S. interest rate reduction. He added that such “change of sentiment” had spurred almost $4 billion in inflows in four weeks.

At this rate, fourth-quarter ETF inflows would deleverage more than 100,000 BTC from issuance, exceeding twice that amount of fresh issuance.

This swift absorbence, alongside decreased long-hold distribution, has allowed Bitcoin to steady up near support levels. Investors now see ETF activity as the brightest beacon for market direction.

Uptober Momentum Builds Ahead of Key U.S. Events

Historically, October was one of Bitcoin’s strongest months, usually referred to as “Uptober” among traders. This year is not an exception. ETF inflows, seasonality, and dissolving macro pressures conspire to form an encouraging digital asset backdrop.

But various upcoming events may swing Bitcoin in its next direction. Traders have been keenly looking at Federal Reserve Chair Jerome Powell’s next speech, in addition to the publication of the newest Federal Open Market Committee minutes.

The delayed U.S. jobs report, dependent on the duration of the government shutdown, also remains a key factor.

Also Read: Bitcoin Breaks New All-Time High Barriers, Can Bulls Push Toward $140K?

Market Opportunity
SOON Logo
SOON Price(SOON)
$0.1582
$0.1582$0.1582
-1.18%
USD
SOON (SOON) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09